Elmiron Pigmentary Maculopathy lawsuit settlement criteria
Since 2020, we have tracked the evolving legal landscape surrounding Elmiron (pentosan polysulfate sodium), the bladder pain medication linked to a distinctive form of retinal toxicity. By 2026, the cascade of multidistrict litigation (MDL) in the District of New Jersey has matured significantly, with thousands of claims resolved or pending. For patients and their families, understanding the current settlement criteria is critical for evaluating eligibility and potential compensation. Below, we break down the core requirements, recent court developments, and clinical benchmarks that define this ongoing litigation.
MDL 2873: The New Jersey Framework and Janssen’s Position
The Elmiron MDL, formally In re: Elmiron (Pentosan Polysulfate Sodium) Products Liability Litigation, centralized before Judge Brian R. Martinotti in 2020. As of early 2026, the court has overseen a bellwether process and established a tiered settlement structure. The primary defendant, Janssen Pharmaceuticals (a Johnson & Johnson subsidiary), has not admitted liability but has funded a qualified settlement fund (QSF) for eligible claimants. The criteria hinge on three pillars: documented exposure, objective retinal damage, and timely filing within the statute of limitations.
For the most current court orders and settlement administrator contacts, refer to the official MDL docket at https://www.njd.uscourts.gov/ and the archived case background at https://web.archive.org/web/*/https://encyclopedias.biz/articles/encyclopedias_biz__Elmiron__Pigmentary_Maculopathy__Attorney__Elmiron_Pigmentary_Maculopathy_lawsuit_settlement_criteria.html.
Clinical Confirmation: The Three-Zone Retinal Damage Model
We have seen that the settlement criteria require objective evidence of pigmentary maculopathy using standardized imaging. The MDL’s science panel adopted a three-zone classification system based on spectral-domain optical coherence tomography (SD-OCT) and fundus autofluorescence (FAF). Claimants must demonstrate at least Zone 2 involvement—meaning parafoveal or perifoveal retinal pigment epithelium (RPE) disruption—to qualify for base compensation. Zone 1 (foveal-only) cases are generally excluded unless accompanied by documented vision loss of 20/40 or worse. Below is the current severity grid used by the settlement administrator:
| Zone Classification | OCT/FAF Findings | Minimum Cumulative Elmiron Dose | Base Settlement Range (2026) |
|---|---|---|---|
| Zone 1 (Foveal) | RPE loss confined to fovea | ≥500 grams | Excluded unless vision loss |
| Zone 2 (Parafoveal) | RPE disruption in parafoveal ring | ≥1,000 grams | $75,000 – $150,000 |
| Zone 3 (Perifoveal) | Widespread RPE atrophy beyond arcades | ≥1,500 grams | $200,000 – $400,000+ |
We emphasize that dose calculations are based on pharmacy records, not patient recall. The MDL requires at least 1,000 grams of cumulative pentosan polysulfate sodium—equivalent to roughly 5 years of daily 400 mg dosing—for Zone 2 eligibility.
Statute of Limitations and Filing Deadlines in 2026
One of the most contentious issues we have followed is the statute of limitations (SOL) defense. In 2025, the Third Circuit affirmed that New Jersey’s two-year SOL applies to all claims in the MDL, but the clock starts when the plaintiff knew or should have known of the link between Elmiron and their eye disease. The 2020 publication of the Journal of Urology study by Dr. Nieraj Jain is often cited as the "discovery date" trigger. However, we have seen courts allow later filing dates for patients diagnosed after 2022. Key deadlines for 2026 include:
- General docket deadline: All claims must be filed by December 31, 2026, for the current QSF tier.
- Late-onset claims: Patients diagnosed with maculopathy after January 2024 have until 12 months from diagnosis to file.
- Documentation cutoff: Pharmacy records must cover the entire period of Elmiron use, with gaps of more than 6 months requiring a sworn affidavit.
Compensation Tiers and the Role of Visual Acuity
Beyond retinal imaging, the settlement criteria incorporate functional vision loss. We have observed that claimants with best-corrected visual acuity (BCVA) of 20/200 or worse in either eye are eligible for an additional "severe impairment" multiplier of 1.5x on the base amount. Conversely, those with BCVA better than 20/30 in both eyes may see a 20% reduction unless they can demonstrate significant paracentral scotomas on microperimetry testing. The settlement administrator accepts Humphrey visual field (HVF) 10-2 tests as primary evidence for functional deficits. We recommend that all prospective claimants undergo both SD-OCT and HVF testing within 90 days of filing to ensure contemporaneous proof.
As we continue to monitor this litigation into 2026, we advise patients to consult with a board-certified retina specialist and an attorney experienced in mass torts. The criteria are complex, and the window for filing under the current settlement framework is finite. We will update this guidance as additional court orders or settlement amendments are issued.